Marshall Wace’s Annovis Bio ANVS Stock Holding History

Marshall Wace’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.43M	Buy	1,842,339 +654,840	+55%	+$1.27M	﹤0.01%	1561
2026 Q1	$2.65M	Buy	1,187,499 +461,637	+64%	+$1.27M	﹤0.01%	1627
2025 Q4	$2.51M	Buy	+725,862	New	+$2.18M	﹤0.01%	1465
2025 Q3	–	Sell	-90,907	Closed	-$197K	–	2865
2025 Q2	$197K	Buy	+90,907	New	+$179K	﹤0.01%	2459
2024 Q1	–	Sell	-32,582	Closed	-$609K	–	2410
2023 Q4	$609K	Buy	+32,582	New	+$289K	﹤0.01%	1642
2022 Q1	–	Sell	-1,679	Closed	-$29K	–	3311
2021 Q4	$29K	Buy	+1,679	New	+$43.3K	﹤0.01%	3662

Other funds holding ANVS

EAM

Empery Asset Management New York $86.5M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Marshall Wace's ANVS Position: Q2 2026 in Review

Marshall Wace increased its Annovis Bio (ANVS) stake by 55% in Q2 2026, buying an estimated $1.27M and bringing the position to 1,842,339 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1561.

Marshall Wace first reported a position in ANVS in Q4 2021 and has held it in 6 quarters since. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

Marshall Wace held 1,842,339 shares of Annovis Bio worth $3.43M as of Q2 2026.
Marshall Wace bought 654,840 Annovis Bio shares in Q2 2026, an estimated $1.27M.
Annovis Bio made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1561 holding.
Marshall Wace first reported a position in Annovis Bio in Q4 2021 and has held it in 6 quarters since.
61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.